What the business is, and whether it's a good one at a fair price.
Operates as a global pharmaceutical formulations platform combining injectable manufacturing in India with an IP-led OTC business in Australia and New Zealand, the latter added through the November 2025 acquisition of a 74.6% stake in Noumed Pharmaceuticals. Revenue flows through three channels: a CDMO export business contributing over 50% of consolidated FY26 revenue under long-term supply contracts into regulated markets; domestic branded formulations in India; and Noumed's OTC and private-label products sold into Australian pharmacy networks. A USD 11 million, 10-year exclusive anti-TB supply contract to the Philippines and an AUD 202 million (~INR 1,300 crore), 7.5-year exclusive OTC supply agreement with Australia's leading pharmacy network are the largest disclosed orders. The company is investing INR 440 crore across India EU-GMP upgrades, an R&D centre and an Adelaide manufacturing facility, all expected to commission by Q4 FY27. Materials are the dominant input cost at 62.5% of revenue, and FY27 revenue is guided at INR 750 crore with a 17% EBITDA margin.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SAI PARENTERALS LIMITED's filed financials and exchange disclosures
SAI PARENTERALS LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SAIPARENT.
Not in the latest reported year — SAI PARENTERALS LIMITED's dividend payout for FY26 was nil.
Effectively yes. It holds ₹97 Cr more cash than debt. Debt stands at 0.65× equity.
On trailing P/E, SAI PARENTERALS LIMITED ranks 164 of 169 in Pharmaceuticals — cheaper than 3% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session SAI PARENTERALS LIMITED moves 1.27% — that is the median absolute close-to-close move across its last 110 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SAI PARENTERALS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
